Overall and cause-specific late mortality after allogeneic BMT
| Study . | Cohort characteristics . | Overall survival . | Relapse-related mortality . | Nonrelapse-related mortality . |
|---|---|---|---|---|
| Atsuta et al8 | 11 047 2-y survivors of allogeneic BMT | 83% at 15 y | 3.7% at 10 y | — |
| Holmqvist et al11 | 1388 2-y survivors of allogeneic BMT in childhood | 79.3% at 20 y | 4.5% | 13.2% at 10 y |
| Martin et al4 | 2574 5-y survivors (autologous or allogeneic BMT [n = 2160]) | 80.4% at 20 y | — | — |
| Wingard et al7 | 10 632 2-y allogeneic BMT survivors | 85% at 10 y | AML, 9%; MDS, 12%; ALL,9%; lymphoma, 11% | |
| Francisco et al2 | 2,999 2-y allogeneic BMT survivors | 68.1% at 20 y | 2.9% at 20 y | 13.9% at 20 y |
| Study . | Cohort characteristics . | Overall survival . | Relapse-related mortality . | Nonrelapse-related mortality . |
|---|---|---|---|---|
| Atsuta et al8 | 11 047 2-y survivors of allogeneic BMT | 83% at 15 y | 3.7% at 10 y | — |
| Holmqvist et al11 | 1388 2-y survivors of allogeneic BMT in childhood | 79.3% at 20 y | 4.5% | 13.2% at 10 y |
| Martin et al4 | 2574 5-y survivors (autologous or allogeneic BMT [n = 2160]) | 80.4% at 20 y | — | — |
| Wingard et al7 | 10 632 2-y allogeneic BMT survivors | 85% at 10 y | AML, 9%; MDS, 12%; ALL,9%; lymphoma, 11% | |
| Francisco et al2 | 2,999 2-y allogeneic BMT survivors | 68.1% at 20 y | 2.9% at 20 y | 13.9% at 20 y |
—, not available; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome.